Since its debut with Karuna, biopharma has stockpiled up 26% on average

Boston-based Karuna Therapeutics Inc. has earned the distinction of the best IPO performer so far in 2019 with a stock price rise of 349% as of its launch in June on the U.S. markets.

Following the positive Phase II high-line data from Karxt in acute psychosis in Schizophrenic patients in November, the inventory skyrocketed, providing a potential reading for wider evidence such as Alzheimer's and painting.

An evaluation....